# A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line

> **NCT04281524** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **CSL Behring**

## Conditions studied

- PICC-associated Thrombosis

## Interventions

- **DRUG:** CSL312
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04281524
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-03
- **Primary completion:** 2021-08
- **Final completion:** 2021-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision non-safety related.
- **Last updated:** 2020-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04281524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04281524, "A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04281524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*